CAN-201

N/A

Report date: 2023/10/26 16:55:55

Base Information

Drug NameCAN-201
Drug Alias NameCAN-201 (利用腺相关病毒（AAV）sL65衣壳的基因治疗疗法)CAN-201
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of Actionα-Galactosidase stimulants
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A